Intranasal Insulin for Weight Management During Smoking Cessation



Status:Completed
Healthy:No
Age Range:18 - 65
Updated:12/12/2018
Start Date:July 2014
End Date:May 2016

Use our guide to learn which trials are right for you!

This FDA-approved (IND# 120700) study will evaluate efficacy of intranasal insulin in
reducing snack intake and reducing postprandial free fatty acid levels in abstinent smokers.


Inclusion Criteria:

- smokers (>10 cig/day) for the past 1 year

- normosmic olfactory function

Exclusion Criteria:

- previous/current use of insulin

- current Diagnostic and Statistical Manual-IV-Revised (DSM-IV-R) Axis I disorder

- current pregnancy (or lactation)

- lifetime history of endocrine disease

- excessive alcohol use (>25 standard units of alcohol/week)

- current use of illicit drugs

- current use of a smoking cessation aid (NRT, Chantix or Wellbutrin), or a psychotropic
agent

- local infections, inflammation, structural abnormalities, or other nasal pathology

- current use of any medications administered intranasally, including intranasal
steroids
We found this trial at
2
sites
Albuquerque, New Mexico 87131
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Albuquerque, New Mexico 87131
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials